Clinical Trials Logo

Clinical Trial Summary

A total of 68 women with pSS and 135 healthy female patients were included in the study. All women in the study and control groups were evaluated gynecologically, and genital findings during the examination and variables related to pSS were recorded. Women's sexual functions were evaluated with the Female Sexual Function Index (FSFI) and quality of life was evaluated using the Health Status Questionnaire-Short Form 36.


Clinical Trial Description

This prospective, single-center, cross-sectional case control study will include a total of 68 women with pSS who presented to the rheumatology outpatient clinic of a tertiary care hospital and 135 healthy females who presented to the gynecology outpatient clinic for reasons other than sexual dysfunction and had similar age and menopausal status to the pSS group. The diagnosis of pSS was made according to the American-European Consensus Group criteria. Age, gravity, parity, body mass index (BMI), education status, smoking status, menarche age, and menopausal status and duration will be recorded for all participants. Disease duration, serum C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), anti-nuclear antibody (ANA) positivity, extractable nuclear antigen antibodies panel, extraglandular involvement and salivary gland pathologies were recorded. Disease-related variables (activity and function data, etc.), European League Against Rheumatism (EULAR) Sjögren's Syndrome Patient Reported Index (ESSPRI), EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI), Clinical Disease Activity Index (CDAI), Disease Activity Score 28 (DAS28), Health Assessment Questionnaire (HAQ), Visual Analog Scale-Pain (VAS-Pain) and fatigue scores and medicines used for pSS will be evaluated and recorded only in the pSS group. A gynecological examination will be performed in the lithotomy position in all participants in both groups by the same gynecologist with at least 15 years of professional experience. In order to determine vaginal atrophy, shrinkage and thinning of the mucosa, loss of rugae in the vagina and introitus stenosis are taken into consideration. The reduction of subcutaneous fat in the labia majora is evaluated as labial atrophy, and contraction in size and even retraction of the clitoral prepuce is interpreted as clitoral atrophy. Pain sensation on speculum examination will be assessed by VAS (rated from 0 to 10). Vaginal culture and cervico-vaginal smear will be analyzed, and the findings will be recorded. Women aged over 20 and under 70 years will be included in the study. Pregnant patients and those with known hepatic, renal, interstitial lung, gynecological oncological diseases, psychiatric disorders, and communication impairment will be excluded from the study. The Female Sexual Function Index (FSFI), Health Status Questionnaire [Short Form (SF)-36], and Hospital Depression and Anxiety Scale (HADS) will be administered to the women in both groups, and their scores were recorded. The data obtained from the study and control groups will be compared. The patients in the pSS group and healthy controls will be further divided into two subgroups according to their menopause status, and statistical comparisons will also be undertaken between these subgroups. A multivariate linear regression analysis will be performed, and the correlation of sexual function with other parameters is examined. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04816370
Study type Interventional
Source Ankara Education and Research Hospital
Contact
Status Completed
Phase N/A
Start date July 2, 2015
Completion date January 25, 2021

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06440525 - A Phase 2 Study of RSLV-132 in Females With Primary Sjögren's Syndrome Phase 2
Not yet recruiting NCT03140111 - LAMELLEYE for the Treatment of Dry Eye Symptoms in pSS Patients N/A
Not yet recruiting NCT06049368 - 68Ga-P16-093 PET/CT Imaging in the Salivary Gland Phase 1/Phase 2
Not yet recruiting NCT03614299 - Eye Dryness Evaluation in Primary Sjögren's Syndrome
Not yet recruiting NCT03126383 - Inflammatory Myopathies in Primary Sjögren's Syndrome N/A
Recruiting NCT04830644 - A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome. Phase 2
Not yet recruiting NCT03765593 - Biomarkers in Primary Sjögren's Syndrome
Completed NCT01081184 - Neurotrophins Implications in Primary Sjögren Syndrome N/A
Completed NCT05670535 - Sjögren and Gynecologic Considerations
Completed NCT03226444 - Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome Phase 1/Phase 2
Completed NCT05380804 - Cutaneous Silent Period Assessment in Primary Sjögren's Syndrome
Terminated NCT04700280 - A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS) Phase 2
Completed NCT03130062 - Resistance Exercise in Woman With Primary Sjörgen Syndrome. N/A
Completed NCT04093531 - Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome Phase 1
Recruiting NCT03509064 - Medico-economic and Quality of Life Impact of Sjogren-associated Small Fiber Neuropathy
Completed NCT04224454 - Vaccine Coverage and Primary Sjögren'Syndrome
Completed NCT04960605 - Prognosis of Dental Implants in Patients With Primary Sjögren's Syndrome N/A
Recruiting NCT06361745 - Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases N/A